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7 Introduction
8 A large body of evidence recentlyQ2 highlighted the invol-
9 vement of long non-coding RNAs (lncRNAs) in cardio-
10 vascular disease [1] and some dysregulated lncRNAs have
11 been associated with diabetic cardiomyopathy [2–5].
12 Among them, a higher expression of the lncRNA metastasis
13 associated lung adenocarcinoma transcript 1 (MALAT1)
14 has been observed in diabetic cardiomyopathy [6, 7].
15 However, a clear understanding of the molecular mechan-
16 isms leading to pathological regulation of lncRNAs in
17 diabetic cardiomyopathy is still missing. Our prior work by
18 Barbati et al. [8], established that, in the presence of high
19 glucose, nitric oxide (NO) signaling derangement might
20 alter the epigenetic landscape of cardiac cells, both in vitro
21 and in vivo, via transcription factor CREM activation.
22Aim
23The present study is aimed at investigating the role of high
24glucose (HG) and NO pathway in the regulation of
25MALAT1 in the heart of mice after 6 months of prolonged
26hyperglycemia and in two cellular models of cardiomyo-
27cytes exposed to HG.
28Methods
29Cell lines, treatments, and RNA interference
30Mouse HL-1 cells and rat H9C2 differentiated into cardio-
31myocytes were cultured and treated with high glucose
32(30 mM) for 72 h, DETANO and Sildenafil as in [8]. CREM
33silencing was performed with siRNA (TriFECTa and
34DsiDNA duplex, Integrated DNA Technologies) according
35manufacture’s instruction as in [8].
36Animal care and treatment
37All experiments were performed in accordance with Eur-
38opean Community guidelines and upon Approval of the
39Italian National Institute of Health (DGSAF0005330 n° 202/
402016-PR) and ethical committee of Università Cattolica as
41described in [8]. Male CD1 mice were made hyperglycaemic
42by streptozotocin (STZ) injection and analyzed at 6 months
43after STZ treatment. Sildenafil treatment were as in [8].
44RNA extraction and qRT
45Analysis was performed as in [8] using the following pri-
46mers designed on (NR_002847) and (XR_350899)
47sequences, respectively:
48mMALAT1 5′-GTAGGTTAAGTTGACGGCCGTTA-
493′ and 5′-ATCTTCCCTGTTTCCAACTCATG-3′;
50rMALAT1 5′-CCTTTTTAATTACTTCAGTTGTAGCT
51TTGAC-3′ and 5′-TGATGGAGCCCAGCAGTTTAG-3′.
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Fig. 1 Nitric oxide counteracts MALAT1 upregulation in cardio-
myocytes exposed to high glucose and in heart of hyperglycemic mice.
a Cluster analysis of down or up-regulated lncRNAs (n= 8, p < 0.05)
in HL-1 cells treated with High Glucose (30 mM) in presence or
absence of DETA/NO vs. Mannitol (30 mM) as control. b ChIP ana-
lysis of CDR1as and MALAT1 promoters in HL-1 cultured in high
and low glucose performed with antibodies reacting to H3K9Ac,
H3K4me3 or H3K36me3. No antibody sample (NoAb) was used as
control. Data represent the mean ± SEM of three independent experi-
ments. *p < 0.05 high glucose vs. low glucose. c MALAT1 expression
was validated in differentiated H9C2 by qPCR. Data are expressed as
fold induction and are mean ± SEM of four independent experiments.
*p < 0.05 high glucose vs. control, $p < 0.05 high glucose plus DETA/
NO or Sildenafil vs. high glucose. d MALAT1 levels analyzed by
qRT-PCR in CD1/Saline (CTR), CD1/STZ mice treated with/without
Sildenafil (STZ+ Sildenafil) at the 3 months time-point after STZ
injection. Sildenafil treatment was administered for 12 weeks. Sample
size for each group is indicated. *p < 0.05 STZ vs. CTR; $p < 0,05
STZ+ Sildenafil vs. STZ. e Evaluation of MALAT1 level in differ-
entiated H9C2 cells transfected with siCREM or scramble in basal
condition (low glucose) and after high glucose treatment (30 mM) of
72 h. Results are mean ± SEM of three independent experiments.*p <
0.05, NS= not significant. f ChIP analysis preformed on MALAT1
promoter with antibodies reactive to CREM, HDAC1, H3K9Ac. The
NoAb condition was used as control. Experiments were performed in
differentiated H9C2 treated with high glucose and cultured in presence
or absence of DETA/NO or Sildenafil. Data are represented mean ±
SEM of three independent experiments. *p < 0.05 high gluc vs. low
gluc; $p < 0.05 high gluc+ Sildenafil vs. high gluc
Endocrine
UN
CO
RR
EC
TE
D P
RO
OF
52 Gene expression by qPCR
53 Analysis was performed as in [9] using LncRNA Profiler
54 qPCR Array Kit (SBI System Biosciences) according
55 manufacturer’s instruction.
56 Chromatin immunoprecipitation (ChIP)
57 ChIP was performed as in [8] using the following primers:
58 mCDR1as promoter 5′-ATATGTCCACGGGTGTACA
59 ATGAT-3′ and 5′-CGGTCTATGGATGAGGCTCTTG-3′;
60 mMALAT1 promoter 5′-CCTTTCCCCTCCGTCGT
61 AGT-3′ and 5′-CCGTGGCGGCAAGGT-3′;
62 rMALAT1 promoter 5′-TGCGAAGGGACACGTCA
63 CT-3′ and 5′-GGCCCACGCACCATCA-3′.
64 Statistical analysis
65 Data are expressed as mean ± SEM as indicated in figure
66 legends. Statistical analyses were performed by using
67 Sigma Plot 13. Significance was calculated using a two-
68 tailed t-test or one-way ANOVA. Differences between
69 groups were calculated with ANOVA and post-hoc Tukey
70 HSD test with Bonferroni correction. A p-value of <0.05
71 was considered significant.
72 Results
73 Nitric oxide counteracts MALAT1 upregulation in
74 cardiomyocytes exposed to high glucose and in
75 heart of hyperglycemic mice
76 Mouse HL-1 and rat cardiomyocytes obtained from differ-
77 entiated H9C2 cells were treated with high glucose for 72 h
78 in the presence or absence of the NO donor, DETA/NO, or
79 the PDE5 inhibitor Sildenafil. In addition, STZ injected CD1
80 mice, treated or not with Sildenafil, have been used as an
81 in vivo model of cardiac damage determined by 6 months of
82 prolonged hyperglycemia. First, we analyzed the expression
83 of 90 lncRNAs in HL-1 cells by qPCR profiling. Among
84 those, a subset of 30 lncRNAs was found expressed in HL-1
85 (Supplemental Fig. 1a). Eight of them (p < 0.05) were sig-
86 nificantly down or up-regulated by HG condition compared
87 to control (Fig. 1a). In this condition, treatment with DETA/
88 NO normalized expression of the lncRNAs modulated by
89 HG (Fig. 1a). To molecularly investigate the mechanism
90 involved in this effect we performed a series of Chromatin
91 immunoprecipitations (ChIPs) on lncRNAs up or down-
92 regulated by HG including CDR1as and MALAT1 (Fig. 1b).
93 Specifically, we studied the enrichment modulation of epi-
94 genetic marks on histone H3 such as tri-methyl lysine 4
95 (H3K4me3), tri-methyl lysine 36 (H3K36me3) and the lysine
969 acetylation (H3K9ac) [10]. In HG, H3K4me3 and
97H3K36me3 were significantly downregulated on CDR1as
98promoter whereas H3K4me3 and H3K9Ac were upregulated
99on that of MALAT1 suggesting that the modulation observed
100at RNA level (Fig. 1a) may rely on transcriptional regulation.
101To further confirm the key role of NO in the HG-dependent
102lncRNA alteration, we used a different cellular model the
103H9C2 cells differentiated into cardiomyocytes and exposed
104to HG in the presence/absence of DETA/NO or Sildenafil
105that directly elevated the intracellular level of NO and cGMP,
106respectively. As expected, MALAT1 upregulation induced
107by HG was significantly counteracted by the co-treatment
108with DETA/NO or Sildenafil (Fig. 1c). Of note, Sildenafil
109was effective in counteracting the negative consequences of
110hyperglycemia also in vivo. Indeed, the heart of STZ-injected
111mice showed a significant increase of MALAT1 in STZ-
112treated mice compared to controls (Fig. 1d). In this condition,
113Sildenafil administrated daily for 12 weeks, starting 3 months
114after STZ injection, rescued the effect of hyperglycemia
115reducing the level of MALAT1 (Fig. 1d). To gain further
116insights about the molecular mechanism controlling the
117expression of MALAT1 in the presence of HG, we analyzed
118the potential involvement in its transcription of transcrip-
119tional factor CREM previously identified as involved in gene
120expression determined by hyperglycemia [8]. Of interest,
121mouse and rat MALAT1 promoters have a similarly struc-
122tured regulatory region at −700 bp from the transcriptional
123start site enriched in CREM binding sites as determined by
124transcription factor database (TRANSFAC 8.3) analysis.
125Remarkably, silencing of CREM in H9C2 cells completely
126abrogated the induction of MALAT1 mediated by HG
127treatment (Fig. 1e). ChIP analysis of MALAT1 promoter
128(Fig. 1f) revealed a significant CREM recruitment in the
129presence of HG. A condition which was inhibited by DETA/
130NO or Sildenafil. In parallel, the enrichment of H3K9Ac in
131the presence of HG was completely rescued by treatment
132with DETA/NO or Sildenafil. On the opposite, the recruit-
133ment of the Histone Deacetylase 1 (HDAC1), reduced by
134HG, was normalized in the presence of DETA/NO or Sil-
135denafil. Accordingly, ChIP performed on cardiac chromatin,
136isolated 6 months after STZ treatment, showed a significant
137increase of CREM binding on MALAT1 promoter in STZ
138vs. saline-treated mice paralleled by an induction of H3K9ac
139level and a reduction of HDAC1 occupancy (Supplemental
140Fig. 1b) thus further confirming CREM as mediator of
141hyperglycemia-dependent MALAT1 upregulation in vivo.
142Discussion
143Taken altogether, these data suggest that Sildenafil coun-
144teracts the increase of MALAT1 occurring in cardiomyo-
145cytes as a consequence of elevated glucose levels in vitro
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146 and in vivo. In light of the present data we reasoned that the
147 following considerations might be extrapolated: (i) reduc-
148 tion of nitric oxide or cGMP bio-availability caused by
149 prolonged hyperglycemia impairs lncRNA expression and
150 (ii) Sildenafil, restoring function of nitric oxide signaling
151 normalized MALAT1 expression levels. To our knowledge,
152 this is the first observation that nitric oxide signaling is
153 involved in the transcriptional regulation of MALAT1, a
154 lncRNA possibly implicated in glucose sensing and diabetic
155 cardiomyopathy.
156 Reduction of NO bio-availability is an early and key
157 determinant in diabetic cardiomyopathy impairing both
158 endothelial and cardiac function ([11] and references
159 therein). The present study reveals that restoring the intra-
160 cellular impact of NO signaling might be important to
161 reverse the effect of hyperglicemia also controlling tran-
162 scription of lncRNAs involved in cardiac injury and in the
163 development of cardiomyopathy associated to dysmetabolic
164 conditions including diabetes. Indeed, this mechanism
165 might be part of a more complex process determining the
166 cardioprotective effect of Sildenafil in heart failure [12, 13]
167 as well as in diabetic cardiomyopathy [14, 15] suggesting
168 novel therapeutics strategies in the presence of prolonged
169 hyperglycemia.
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